Payment overview · 2025
General Payments
$1,547.70
93 reported records · 24 companies
Healthcare provider profile · identity verified
Amanda Lynn Morris, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · SAINT JOSEPH, MI · NPI 1730479270
Verified facts
What the public records show
CMS Open Payments records show Amanda Lynn Morris, DO received $1,547.70 in general payments during 2025 across 93 reported records.
Xeris Pharmaceuticals, Inc. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Korlym, Mounjaro, Ozempic, Recorlev, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
Xeris Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RECORLEV as an associated drug or biological on 10044 records involving 3629 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Recorlev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $262.72 | 17.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $239.95 | 15.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.79 | 12.6% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.03 | 9.9% | 10 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $69.74 | 4.5% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $63.49 | 4.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.91 | 3.4% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $47.15 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.15 | 3.0% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $41.11 | 2.7% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $37.70 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.30 | 2.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.16 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.92 | 2.3% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $31.77 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.09 | 1.9% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $25.47 | 1.6% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $25.40 | 1.6% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.63 | 1.6% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $23.60 | 1.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.19 | 1.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.44 | 1.1% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $16.60 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.39 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,547.70 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $170.38 | 4 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $140.06 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.48 | 11 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $92.34 | 8 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $74.33 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.31 | 7 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $69.74 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $63.49 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $47.15 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.41 | 4 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $41.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $31.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $27.61 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.61 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.28 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 276 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 183 | exact normalized | Medicare Part D |
| RECORLEV recorlev |
2025 | Recorlev | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 30 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
276 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
114 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
183 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Xeris Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | RECORLEV open payments reported associated product |
CMS Open Payments — General Payments 10044 supporting records · 3629 recipient NPIs · example record 1250146588 |
Recorlev · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 775 | 195 |
| Mounjaro | Tirzepatide | 276 | 52 |
| Ozempic | Semaglutide | 183 | 38 |
| Metformin Hcl | Metformin Hcl | 168 | 46 |
| Methimazole | Methimazole | 123 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 120 | 37 |
| Trulicity | Dulaglutide | 114 | 27 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 107 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 38 |
| Farxiga | Dapagliflozin Propanediol | 97 | 24 |
| Jardiance | Empagliflozin | 82 | 30 |
| Liothyronine Sodium | Liothyronine Sodium | 80 | 27 |
| Hydrocortisone | Hydrocortisone | 72 | 22 |
| Synthroid | Levothyroxine Sodium | 69 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 67 | 37 |
| Glipizide Er | Glipizide | 59 | 13 |
| Spironolactone | Spironolactone | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 19 |
| Novolog | Insulin Aspart | 47 | 18 |
| Glimepiride | Glimepiride | 46 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | 18 |
| Losartan Potassium | Losartan Potassium | 44 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 12 |
| Gabapentin | Gabapentin | 43 | suppressed |
| Humalog | Insulin Lispro | 40 | 14 |
| Lisinopril | Lisinopril | 40 | 16 |
| Cinacalcet Hcl | Cinacalcet Hcl | 36 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 35 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Prednisone | Prednisone | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 20 |
| Fluconazole | Fluconazole | 25 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Levoxyl | Levothyroxine Sodium | 23 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 22 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Admelog | Insulin Lispro | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Unithroid | Levothyroxine Sodium | 18 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Korlym | Mifepristone | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Recorlev | Levoketoconazole | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,547.70 · 93 records | Xeris Pharmaceuticals, Inc. | AREXVY, Bimzelx, CREON, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Gazyva, IMCIVREE, ISTURISA, JARDIANCE, Kineret, Korlym, LEQVIO, LINZESS, MOUNJARO, OPSUMIT, Omnipod, Ozempic, PROLIA, RECORLEV, REPATHA, REZDIFFRA, RINVOQ, Rybelsus, SHINGRIX, SKYRIZI, TEPEZZA, TONMYA, TWIIST, UPTRAVI, VYVGART, Wegovy, Yorvipath, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error